These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34155478)

  • 1. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome and Risk Signature Analysis.
    Liu Y; Ren Y; Ge S; Xiong B; Zhou G; Feng G; Song S; Zheng C
    Front Oncol; 2021; 11():662408. PubMed ID: 34155478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
    Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
    Acad Radiol; 2024 Nov; 31(11):4456-4465. PubMed ID: 38760273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study.
    Xia WL; Zhao XH; Guo Y; Cao GS; Wu G; Fan WJ; Yao QJ; Xu SJ; Guo CY; Hu HT; Li HL
    Front Oncol; 2022; 12():961394. PubMed ID: 36249011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
    Guo J; Wang W; Zhang Y; Xu L; Kong J
    J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Zheng Y; Xiang Y; Shi H; Lin Z; Cheng S; Zhu J
    J Hepatocell Carcinoma; 2024; 11():1079-1093. PubMed ID: 38882440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma.
    Zhang W; Chen L; Cao Y; Sun B; Ren Y; Sun T; Zheng C
    Cancer Manag Res; 2021; 13():5391-5402. PubMed ID: 34262347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
    Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
    J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Gao B; Yang F; Zheng D; Hu S; Liu J; Liu H; Liu Y; Liu L; Wang R; Zhao Y; Cui C; Fang C; Yang J; Su S; Han Y; Yang X; Li B
    J Hepatocell Carcinoma; 2023; 10():2265-2276. PubMed ID: 38107541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC.
    Sun T; Ren Y; Sun B; Chen L; Zhu L; Zhang L; Zheng C
    J Hepatocell Carcinoma; 2023; 10():447-457. PubMed ID: 36960308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study.
    Ouyang T; Liu J; Shi C; Zhu L; Guo X
    J Hepatocell Carcinoma; 2021; 8():1459-1471. PubMed ID: 34858890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Kan X; Liang B; Zhou G; Xiong B; Pan F; Ren Y; Cao Y; Wang J; Yang F; Zheng C
    Front Oncol; 2020; 10():970. PubMed ID: 32733791
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.
    Cao F; Shi C; Zhang G; Luo J; Zheng J; Hao W
    BMC Cancer; 2023 Sep; 23(1):873. PubMed ID: 37718456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.
    Chen ML; Wu CX; Zhang JB; Zhang H; Sun YD; Tian SL; Han JJ
    Front Endocrinol (Lausanne); 2022; 13():996228. PubMed ID: 36187118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.
    Qin J; Huang Y; Zhou H; Yi S
    Front Oncol; 2022; 12():807102. PubMed ID: 35463356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancer Stage B hepatocellular carcinoma: A propensity score matching study.
    Li X; Chen B; An C; Cheng Z; Han Z; Liu F; Yu J; Liang P
    J Cancer Res Ther; 2020 Sep; 16(5):1027-1037. PubMed ID: 33004744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Deng L; Sun Y; Wang H; Liao C; Li D; Xu G; Yang X
    J Hepatocell Carcinoma; 2024; 11():29-38. PubMed ID: 38223554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
    Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
    J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.